Addressing the rate-limiting step in mRNA vaccine screening
A new paradigm for mRNA synthesis
WHITE PAPER: Addressing the rate-limiting step in mRNA vaccine screening:
A new paradigm for mRNA synthesis

mRNA as a vaccine platform has demonstrated recent success and promises tremendous potential, but there are still challenges that need to be addressed to realize its full potential. This whitepaper addresses a key challenge in mRNA-based vaccine discovery workflows: mRNA synthesis.
In this whitepaper you will learn:
- How long and inefficient workflows for mRNA synthesis can impact delays in vaccine candidate screening and evaluation.
- Why current mRNA synthesis options are not optimal to realize the full potential of mRNA-based therapeutic vaccine application.
- How using advances in synthetic biology automation can produce synthetic mRNA overnight, promoting vaccine optimization and eliminating weeks of wait time from design to assessment.
Complete the adjacent form today for access to the white paper.
"*" indicates required fields
By clicking submit, you agree that Telesis Bio may use this information to contact you about our programs, products, or services. You may opt out at any time.
Your personal data is handled according to our privacy policy. In addition, if you are located within a distributor territory, you may be contacted directly by them. We never sell your data to anyone.